IL17RA and systemic sclerosis: Administration of anti‐IL‐17RA mAb significantly inhibited the key phosphorylated proteins of the NF‐kB and MAPK pathways in SSc DFs that were upregulated by rChi3L1 (Figure S11A, Supporting Information).